Latest News

Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors 02/21/17
Leslie Trigg Retires after Seven Years of Service. Cardiovascular Systems (CSI) (NASDAQ: CSII) today announced the addition of independent board member Martha Goldberg Aronson, an experienced business executive with deep healthcare and medical industry experience. Aronson replaces director Leslie Trigg, who is retiring after seven years of service. The CSI board continues to have seven directors, six of whom are independent. “Leslie provided thoughtful guidance and valuable counsel to our company throughout her tenure on our Board,” said Scott Ward , CSI chairman, president and chief executive officer. “Her experience and perspectives helped shape CSI’s strategy and prepared our company to be the leader in the atherectomy market. We thank Leslie for her years of service to CSI, and we are pleased to welcome Martha Goldberg Aronson to CSI.” From 2012 to 2016, Aronson served as the executive vice president and president of Global Healthcare at Ecolab, Inc., where she was responsible for...
Cardiovascular Systems Releases 1-Year Results from COAST IDE Study in Late-Breaking Presentation at 2017 Cardiovascular Research Technologies Conference 02/20/17
Information shared about the Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) Micro Crown, for patients with severe coronary calcium, includes: Low TLR rate of 6.3% and Q-wave MI rate of 2.0% at 1-year 1-year revascularization rates within range of DES literature Provides additional information for this device which is currently under review for commercial approval in the U.S. and Japan. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today released 1-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation at the 2017 Cardiovascular Research Technologies (CRT) conference in Washington, D.C. The COAST study is CSI’s prospective, single-arm, multi-center, global IDE trial to evaluate the safety and efficacy of the company’s next-generation Micro Crown orbital atherectomy technology in treating patients with severely calcified coronary lesions. It follows the pivotal ORBIT II trial of the company’s Diamondback 360® Coronary...

Latest SEC Filings

Date Filing Description Download
03/02/17 4 Statement of Changes in Beneficial Ownership
03/02/17 4 Statement of Changes in Beneficial Ownership

Stock Chart